Glycominds Ltd. holds extensive knowledge and experience in the field of glycomics, utilized for the discovery and development of unique glycan biomarkers which enable high-value medical diagnostics.
Glycominds is developing and commercializing a new class of novel blood tests which allow physicians to detect cancer earlier, predict autoimmune disease progression and decide on therapy regimen.
Autoimmune Decisions™
Our leading products are the IBDX®, a blood tests for Inflammatory Bowel Disease (IBD) diagnostics and Crohn's Disease severity
assisting physicians in early and quick diagnosis and in fitting the appropriate course of treatment for CD patients, and the gMS™ a blood test for the prediction of patients with clinical isolated syndrome suggestive of MS converted to clinically definitive Multiple Sclerosis. This powerful test will enable physicians to take post-CIS treatment decisions.
We believe in advanced autoimmunity tests that will improve the quality of life for millions of patients
 more
|
|
|
